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ABSTRACT
Human b-defensins (hBDs) are the most abundant antimicrobial peptides in epithelial cells, and
function in the host immune system. Respiratory epithelial cells express hBDs to inhibit bacterial
proliferation during respiratory tract infections. The aim of this study was to investigate the release of
hBDs into the respiratory tract and their benefit as a host defence system in chronic Pseudomonas
aeruginosa infections. The levels of four hBD peptides (hBD-1–hBD-4) were measured in the bronchial
epithelial lining fluid (ELF) of nine patients with chronic lower respiratory tract infection caused by
P. aeruginosa. Eight patients with idiopathic pulmonary fibrosis and eight volunteers free of pulmonary
disease were recruited as controls. ELF was obtained by bronchoscopic microsampling and hBD levels
were measured by radioimmunoassays. The antimicrobial effects of hBDs were studied individually and
in combination using an in-vitro colony count assay for P. aeruginosa. Concentrations of hBD-1 and hBD-
3 tended to be higher in patients with chronic lower respiratory tract infection than in the controls. hBD-
2 and hBD-4 were detected in ELF from five and four of nine patients, respectively, but the hBD levels in
controls were all below the limits of detection. All patients with infection caused by mucoid P. aeruginosa
had detectable hBD-2 and hBD-4 levels in ELF. In-vitro colony count assays showed a potential
synergism between hBD-2 and hBD-4 in inhibiting bacterial proliferation. The findings indicate that
hBDs, especially hBD-2 and hBD-4, are pathophysiologically important in infections caused by mucoid
strains of P. aeruginosa.
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INTRODUCTION
The lungs are in direct contact with the environ-
ment through the airways, and therefore an
analysis of innate immunity in the airways is the
first stage in clarifying the pathogenesis of chronic
lower respiratory tract infection. Such infections
lead to a serious deterioration of lung function,
and are usually associated with persistent coloni-
sation by Pseudomonas aeruginosa, Haemophilus
influenzae and Streptococcus pneumonia [1]. In
particular, P. aeruginosa is a difficult pathogen to
eradicate because of its formation of biofilm and
resistance to a wide range of antibiotics [2,3].
Defensins are the most abundant antimicrobial
peptides, and comprise a-defensin in neutrophils
and b-defensin (hBD) in epithelial cells. Defensins
are endogenous, cationic, cysteine-rich antimicro-
bial peptides that form part of the first line of host
defence against bacterial infections; thus, hBDs
released from bronchial epithelial cells can inhibit
microbial proliferation [4]. To date, four hBDs
have been isolated and shown to be localised in
pulmonary epithelial cells for airway mucosal
defence in humans, although they are also
expressed in organs other than the lungs [5–10].
A previous study measured blood hBD peptide
concentrations in patients with infection [11,12].
Serum hBD-2 concentrations were high during
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the active stage of infection and returned to
normal during the recovery stage, whereas hBD-
1 concentrations showed no marked changes
throughout the clinical course. Since hBDs may
be induced in organs other than the lungs during
the course of infection, it remains unclear whether
the kinetics of hBDs in blood accurately reflect
their expression kinetics in respiratory epithelial
cells. Furthermore, it is not known whether hBDs
are released from the bronchial epithelium in
sufficient concentrations to inhibit proliferation of
P. aeruginosa.
Previous reports have demonstrated induction
of inflammatory mediators from respiratory epi-
thelial cells and the activation of signalling path-
ways in vitro in response to P. aeruginosa infection
[13,14], although antimicrobial peptides have not
been quantified in the epithelial lining fluid (ELF)
of humans with chronic lower respiratory tract
infection. The lack of a method to obtain the
surface fluid of airway epithelial cells in vivo in
humans has previously hindered attempts to
measure the levels of antimicrobial peptides in
ELF. However, a sampling method for ELF has
recently been developed [15], thereby facilitating
further molecular analyses of the mucosal defence
system of the airways in vivo.
The present study determined the concentra-
tions of hBDs in ELF from patients with chronic
lower respiratory tract infection by means of
radioimmunoassays (RIAs) and microsampling
through bronchoscopy. In addition to hBDs,
respiratory epithelial surface secretions involved
in host defence include lysozyme, lactoferrin,
secretory phospholipase A2 and other antimicro-
bial peptides [16]. There appears to be some
synergy among these compounds with regard to
reinforcing the antibiotic effect, e.g., between
hBD-4 and lysozyme [17]. Therefore, a second
aim of the present study involved testing the
hypothesis that the net antimicrobial activity of
hBDs against P. aeruginosa in vitro is representa-
tive of the interaction kinetics between these
proteins.
PATIENTS AND METHODS
Patients
Nine patients with chronic P. aeruginosa lower respiratory
tract infection were enrolled in the present study between
September and December 2004. Microbiological specimens
examined routinely were sputum or tracheal aspirate cul-
tures. The purulence of samples was confirmed macroscop-
ically by the investigators. Valid samples (<10 squamous
epithelial cells and >25 polymorphonuclear leukocytes ⁄ low-
power (·100) magnification field) were cultured for pathogen
identification.
Laboratory data included peripheral white blood cell
counts, serum C-reactive protein (CRP) values and P. aerugi-
nosa phenotypes. The following inclusion criteria were
required for enrolment: (i) persistent productive cough with
purulent sputum for >6 months; and (ii) isolation of P. aeru-
ginosa from sputum or tracheal aspirate cultures. The follow-
ing were exclusion criteria: (i) steroids, immunosuppressants
or any antibiotics prescribed within the previous 3 months; (ii)
cancer or diabetes mellitus; and (iii) detection of non-bacterial
pathogens such as mycobacteria and fungi in specimens.
To compare hBD levels, eight volunteers free of pulmonary
disease (aged 65 ± 11 years; five males and three females) and
eight patients with idiopathic pulmonary fibrosis (aged
66 ± 11 years; five males and three females) were recruited
as examples of individuals with non-infectious pulmonary
disease. The former group of volunteers had no pulmonary or
infectious disease, as confirmed by interviews, laboratory data
and chest X-rays. Idiopathic pulmonary fibrosis was diagnosed
according to the guidelines of the American Thoracic Society
[18].
Blood was obtained from all subjects immediately before
bronchoscopy in order to measure serum levels of hBD-1–
hBD-4, peripheral blood counts and CRP levels. Blood samples
from the ante-cubital vein were drawn into tubes containing
EDTA. The samples were immediately immersed in iced water
and centrifuged at 3000 g within 1 h. The serum was aspirated
and stored at )80C until analysis. All controls and patients
gave written informed consent, and the Research Ethics
Committee of Miyazaki University approved the study in
advance.
Bronchoscopic microsampling (BMS)
ELF was obtained using the BMS method. The BMS probe
(Olympus Co., Tokyo, Japan) and sampling procedure have
been described in detail previously [15]. In brief, each subject
was injected intramuscularly with hydroxyzine and the upper
respiratory tract was locally anaesthetised with a few milli-
litres of lidocaine 2% v ⁄v. A flexible BF-XT40 fibreoptic
bronchoscope (Olympus) was then inserted into the right
bronchus. After one channel of the bronchoscope was flushed
with air, the BMS probe was inserted through the channel
into a segmental bronchus of the right lower lobe. The inner
probe was then advanced slowly into the distal airway, and
sampling of ELF was performed by gently maintaining the
probe at the site of the targeted bronchial wall for 10 s to
absorb the ELF. The inner probe was then withdrawn into the
outer tube, and both devices were withdrawn simulta-
neously. The wet inner probe was cut 3 cm proximal to its
tip and placed in a previously weighed tube. A dilution was
then prepared by adding 3 mL of saline to the tube and
vortexing for 1 min [15]. The diluted solution was transferred
to a new tube and stored at )20C. The probe was then dried
and weighed again to measure the ELF volume recovered.
The concentration of hBD in ELF (hBDELF) was determined as
follows:
hBDELF ¼hBDBMSð3þELF volumeÞ=ELF volume
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where hBDBMS is the measured concentration of hBD in the
saline-diluted sample. The ELF volume was calculated as
described previously [15].
Measurement of concentrations of hBD-1–hBD-4
The concentrations of hBD-1–hBD-4 were measured by the
RIA method described previously [11,12]. hBDs were radio-
iodinated by the lactoperoxidase method, with 125I-labelled
peptide being purified by reverse phase HPLC on a column
(model TSK ODS 120A; Tosoh Co., Tokyo, Japan). The
incubation buffer for the RIA was 50 mM sodium phosphate
(pH 7.4) containing bovine serum albumin 0.25% w ⁄v treated
with N-ethylmelemide, 80 mM NaCl, 25 mM EDTA, NaN3
0.05% w ⁄v, Triton X-100 0.1% v ⁄v, and dextran T-40 3.1%
w ⁄v. The diluted sample, or a standard peptide solution
(100 lL), was incubated for 24 h with 100 lL of diluted
antiserum (final dilutions for hBD-1–hBD-4 were 1:460 000,
1:420 000, 1:1000 000 and 1:2100 000, respectively). The anti-
serum was prepared by conjugation of hBD to bovine
thyroglobulin using 1-ethyl-3-(3-dimethylaminopropyl)-carbo-
diimide-HCl, followed by five rounds of dialysis against 2 L
of NaCl 0.9% w ⁄v to remove unconjugated material. An
antigenic conjugate solution (0.9–3.0 mL) was used to immu-
nise three New Zealand white rabbits by multiple intra-
cutaneous and subcutaneous injections. The animals were
given booster injections every 2 weeks, and were bled 7 days
after each injection. All experimental protocols were ap-
proved by the Ethics Review Committee for Animal Experi-
mentation of Miyazaki University. The tracer solution
(16 000–18 000 cpm in 100 lL of solution) was added to the
sample and the mixture was incubated for 24 h, after which
normal rabbit serum and anti-rabbit IgG goat serum were
added and the whole preparation was stored for 16 h. Bound
and free ligands were separated by centrifugation. All
procedures were performed at 4C, and the samples were
assayed in duplicate. None of the antisera exhibited cross-
reactivity for human neutrophil peptide-1 and hBD-1–hBD-4.
The lowest detection limits in the assay were 0.1 pg ⁄ lL,
10 pg ⁄mL, 60 pg ⁄mL and 6 pg ⁄mL for hBD-1–hBD-4,
respectively.
Bactericidal assay
The bactericidal activities of hBD were examined in a colony
count assay using P. aeruginosa strain PAO1 (supplied by T.
Hayashi, Miyazaki University, Japan) [12]. Bacteria (5000 CFU)
were incubated for 2 h at 37C in 50 lL of incubation medium
containing various concentrations of hBDs. The incubation
medium closely resembled the tracheal milieu (Na+ 95 mEq ⁄L,
Cl– 90 mEq ⁄L, K+ 25 mEq ⁄L, osmolarity 210 mOsm ⁄ kg,
pH 7.1). The incubation mixtures were diluted serially, spread
on nutrient agar plates, and incubated for 18 h at 37C, after
which the colonies were counted. The bactericidal activity was
expressed as the colony reduction ratio, i.e., the percentage of
killed bacteria compared to the percentage killed in the
control. For evaluation of potential synergism between an
individual hBD and other hBDs, a colony count assay was
used in combination with serial two-fold dilutions of peptides
[19]. Fractional inhibitory concentration (FIC) indices were
calculated as follows:
½AÞ=MICAþ ½BÞ=MICB ¼ FICAþFICB ¼ FIC index
where MICA and MICB are the MICs of drugs A and B,
determined separately, and A and B are the MICs of drugs A
and B when determined in combination [20,21]. Drug inter-
actions were considered synergic when the FIC index was <0.5,
and antagonistic when the FIC index was >2.0.
Statistical analysis
Data were expressed as means ± standard deviation. Differ-
ences among groups were examined using the Mann–Whitney
U-test. Correlations between two groups were determined
using Spearman’s rank correlation analysis. A p value <0.05
was considered to be statistically significant.
RESULTS
Patient characteristics
The nine patients (six females) with chronic lower
respiratory tract infection were aged 75 ± 9 years
(range 64–89 years). Underlying diseases were
bronchiectasis (n = 4), diffuse panbronchiolitis
(n = 2), and neurological diseases (n = 3; amyo-
trophic lateral sclerosis, Parkinson’s disease and
cerebral infarction). Although patients with chro-
nic lower respiratory tract infection tended to be
older than controls, there were no significant
differences in age or gender among the three
groups. Laboratory data revealed white blood cell
counts of 5909 ± 1364 ⁄ lL and CRP concentrations
of 3.9 ± 2.1 mg ⁄dL. P. aeruginosa in samples ob-
tained from patients with lower respiratory tract
infection had mucoid (n = 3) and non-mucoid
(n = 6) phenotypes. Five patients with chronic
lower respiratory tract infection yielded bacteria
other than P. aeruginosa from specimens (Escheri-
chia coli, two patients; Acinetobacter lwoffii, Steno-
trophomonas maltophilia and Serratia marcescens,
one patient each).
hBD values in plasma and ELF obtained by
BMS
Serum hBD-1, hBD-2 and hBD-3 levels were
10.3 ± 4.6 ng ⁄mL, 487.1 ± 907.0 pg ⁄mL and
486.4 ± 227.4 pg ⁄mL, respectively, in patients
with chronic lower respiratory tract infection
(Fig. 1). The serum concentration of hBD-4 was
below the limit of detection in every patient. The
hBD-2 and hBD-3 serum concentrations in pa-
tients with chronic lower respiratory tract infec-
tion tended to be higher than in the controls.
Fig. 2 shows hBD concentrations in the ELF of
patients with chronic lower respiratory tract
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infection and controls. Concentrations of hBD-1
and hBD-3 in ELF seemed to be higher in patients
with chronic lower respiratory tract infection.
hBD-2 and hBD-4 were detectable in ELF from
five and four patients, respectively, of the nine
patients with chronic lower respiratory tract
infection, although the concentrations in control
subjects were all below the limit of detection.
hBD-2 and hBD-4 were detected in ELF from all
patients infected with a mucoid P. aeruginosa
Fig. 1. Human b-defensin (hBD)
concentrations in serum from
healthy volunteers (HV), patients
with idiopathic pulmonary fibrosis
(IPF) and patients with chronic low-
er respiratory tract infection (CRI).
In the CRI group, open circles indi-
cate patients infected with a mucoid
strain of Pseudomonas aeruginosa, and
closed circles indicate patients infec-
ted with a non-mucoid phenotype of
P. aeruginosa.
Fig. 2. Human b-defensin (hBD)
concentrations in epithelial lining
fluid from healthy volunteers (HV),
patients with idiopathic pulmonary
fibrosis (IPF) and patients with chro-
nic lower respiratory tract infection
(CRI). In the CRI group, open circles
indicate patients infected with a
mucoid phenotype of Pseudomonas
aeruginosa, and closed circles indi-
cate patients infected with a non-
mucoid phenotype of P. aeruginosa.
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strain. The serum concentrations of hBD-1 corre-
lated inversely, while those of hBD-2 and hBD-4
correlated positively, with serum CRP levels
(Table 1).
Bactericidal activity of hBDs against
P. aeruginosa
The bactericidal activities of hBDs for P. aerugi-
nosa were studied using colony count assays. The
MIC50s of hBD-2, hBD-3 and hBD-4 against
P. aeruginosa were 1.1, 0.9 and 0.9 mg ⁄L, respect-
ively, while the MIC50 of hBD-1 was too low to
measure. The combination of hBD-2 and hBD-4
displayed potential synergy in decreasing the
MIC50, whereas the combinations of hBD-2 and
hBD-3, and of hBD-3 and hBD-4, increased the
MIC50 (Table 2).
DISCUSSION
This is the first report demonstrating differences
in production and kinetics between hBDs in lower
respiratory tract infection. As shown in previous
reports [22,23], hBDs participate in the pathogen-
esis of pulmonary diseases involving chronic
lower respiratory infection. Furthermore, hBDs
play an important role in antimicrobial defence in
diffuse panbronchiolitis and mycobacterial infec-
tions, whereas inactivation of hBDs, following
changes in airway surface liquid composition in
the lungs of patients with cystic fibrosis, contri-
butes to bacterial colonisation by P. aeruginosa
and other bacteria [24]. hBD-1 and hBD-3 concen-
trations in ELF from patients with P. aeruginosa
infection tended to be high, and hBD-2 and hBD-4
concentrations in ELF were detectable in patients
with infections caused by a mucoid strain of
P. aeruginosa. Although hBDs might be undetec-
ted by the RIA because of dilution following
sampling of a very small volume of the original
sample, hBD-2 and hBD-4 were not detected in
ELF from four and five patients, respectively, of
six patients with infections caused by a non-
mucoid strain of P. aeruginosa. Thus, hBD-2 and
hBD-4 seem to play a role in infection with
mucoid P. aeruginosa. Based on the observation
that serum hBD-4 levels were below the detection
level in all subjects, but hBD-4 was detectable in
ELF from four patients with chronic lower res-
piratory tract infection, it seems that hBD-4 might
be expressed locally by respiratory tract epithelial
cells. All measured hBD concentrations were
higher in ELF than in serum; therefore, the high
hBD levels in serum may be induced by inflow
from respiratory epithelial cells to blood, rather
than by production from blood cells. The quan-
tification of serum and ELF hBD levels revealed
that the kinetics of hBDs in blood do not reflect
accurately their expression kinetics in respiratory
epithelial cells.
ELF hBD concentrations were not sufficient to
suppress the proliferation of P. aeruginosa in vitro;
however, hBD-2 and hBD-4 peptides exhibited
potential synergism against P. aeruginosa. hBD-2
represents a major inducible antimicrobial factor
released by airway epithelial cells upon contact
with mucoid P. aeruginosa, but the bactericidal
activity of hBD-4 against P. aeruginosa is stronger
than that of other hBDs [8]. The synergism of
hBD-2 and hBD-4 suggests the presence of dis-
tinct points of action for hBDs. It was not possible
to elucidate the mechanism by which the combi-
nation of hBD-2 and hBD-3, and that of hBD-3 and
hBD-4, increased the MIC50. All hBDs have a
similar structure, and their antimicrobial proper-
ties are related to the formation of cellular
membrane pores or the permeabilisation of cells
by electrostatic interaction, although their antimi-
crobial activities differ. hBD-1 is expressed con-
stitutively in the absence of stimulation [4], but
hBD-2, hBD-3 and hBD-4 are induced in response
Table 1. Correlations between serum C-reactive protein
and human b-defensin (hBD) concentrations in bronchial
epithelial lining fluid
Correlation coefficient p
hBD-1 )0.55 0.004
hBD-2 0.62 0.003
hBD-3 0.48 0.814
hBD-4 0.43 0.005
Table 2. Antimicrobial activities of human b-defensins
(hBDs) for Pseudomonas aeruginosa
MIC50 (mg ⁄mL) FIC index
Alone
hBD-2 1.1 –
hBD-3 0.9 –
hBD-4 0.9 –
Combination
hBD-2 ⁄ 3 1.46 2.96
hBD-2 ⁄ 4 0.08 0.20
hBD-3 ⁄ 4 3.75 3.93
FIC, fractional inhibitory concentration.
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to lipopolysaccharide, being induced by nuclear
factor-jB, signal transducer, and activator of
transcription and protein kinase C, respectively
[16,25,26]. Based on an analysis of DNA copy
number variation across chromosome band
8p23.1, hBD-2, hBD-3 and hBD-4, but not hBD-1,
are located in a DNA repeat region [27]. There-
fore, any variations in the levels of hBD-2, hBD-3
and hBD-4 seem to reflect a difference in the
number of repeats, whereas the higher level of
hBD-1 is likely to be associated with the disease
[28]. Taken together, these findings suggest that
the antimicrobial activity of the various hBDs may
be related to differences in the molecular mech-
anism of action.
Although the number of patients in the present
study was small, hBD-2 and hBD-4 levels in ELF
were related closely to serum CRP values. In
contrast, the hBD-1 level in ELF correlated
inversely with CRP values. There appears to be a
difference between hBD-1 and hBD-2–hBD-4 in
terms of the kinetics of the immune response
against respiratory infections. The synergism of
hBD-2 and hBD-4 emphasises the important role of
the antimicrobial action of hBDs, even if they were
not present at sufficient concentrations to suppress
the proliferation of P. aeruginosa. Although the
bactericidal activity of ELF in human bronchus
seems to be different from that in cultured cells,
because of surface liquid composition and the
presence of other proteins, the results emphasise
the importance of at least hBD-2 and hBD-4 in the
human response to P. aeruginosa infection.
The present study used P. aeruginosa to
investigate the defence mechanism in respiratory
epithelial cells. Antibiotic-resistant P. aeruginosa
has emerged recently as the most important
bacterial pathogen in chronic lower respiratory
tract infection. Diffuse panbronchiolitis is a
chronic lower respiratory tract disease that
requires treatment for P. aeruginosa during the
clinical course. Long-term macrolide therapy
improves the life-expectancy of patients with
diffuse panbronchiolitis, but treatment failure in
the case of P. aeruginosa leads to respiratory
insufficiency. When chronic infections are treated
with poorly effective antibiotics, non-mucoid
P. aeruginosa converts into mucoid variants that
are resistant to multiple antibiotics. The respir-
atory mucosal response at the molecular level
may differ between mucoid and non-mucoid
P. aeruginosa variants. A previous report showed
that high concentrations of lipopolysaccharide
induced hBD-2 expression in respiratory epithe-
lial cells [13]. In addition, hBD-2 peptides were
expressed in epithelial cells in response to
mucoid, but not non-mucoid, P. aeruginosa [13].
The alginate capsule produced by mucoid P. ae-
ruginosa, composed mainly of mannuronic acid
polymers, can induce hBDs through activation of
Toll-like receptor 2 [29]. Thus, the production of
the mucoid capsule may be involved in the
release of hBD-2 or hBD-4 from epithelial cells.
Aerosolised antimicrobial agents have recently
been used for treatment of lower respiratory tract
infection [30,31]. Inhalation of aerosolised agents
is a useful delivery system, as adverse effects may
be reduced and the agents reach efficient concen-
trations directly at the site of action. Although the
extent of the cytotoxic reinforcement to epithelial
cells caused by hBD-2 and hBD-4 is completely
unknown, the present data show that the combi-
nation of hBD-2 and hBD-4 may be advantageous
for defence against P. aeruginosa in the respiratory
tract. Further investigations are required to estab-
lish whether aerosolised hBDs could be used to
control respiratory tract infection, and whether
hBDs may be used for the control of lower
respiratory tract infection caused by multidrug-
resistant pathogens. However, the present study
demonstrated the significance of hBDs in ELF as a
host defence system in chronic P. aeruginosa
infections. Furthermore, the findings indicate that
hBDs, especially hBD-2 and hBD-4, are patho-
physiologically important in infections caused by
mucoid P. aeruginosa. Molecular analysis of the
role of hBDs in lower respiratory tract infection
may help to elucidate the mechanisms of infec-
tious diseases.
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